|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A triple-RBD-based mucosal vaccine provides broad protectionagainst SARS-CoV-2 variants of concern显示文摘The rapid mutation and spread of SARS-CoV-2 variants urge the development of effective mucosal vaccines to provide broadspectrum protection against the initial infection and thereby curb the transmission potential.Here,we designed a chimeric tripleRBD immunogen,3Ro-NC,harboring one Delta RBD and two Omicron RBDs within a novel protein scaffold.3Ro-NC elicits potent and broad RBD-specific neutralizing immunity against SARS-CoV-2 variants of concern.Notably,intranasal immunization with 3RoNC plus the mucosal adjuvant KFD(3Ro-NC+KFDi.n)elicits coordinated mucosal IgA and higher neutralizing antibody specificity(closer antigenic distance)against the Omicron variant.In Omicron-challenged human ACE2 transgenic mice,3Ro-NC+KFDi.n immunization significantly reduces the tissue pathology in the lung and lowers the viral RNA copy numbers in both the lung(85.7-fold)and the nasal turbinate(13.6-fold).Nasal virologic control is highly correlated with RBD-specific secretory IgA antibodies.Our data show that 3Ro-NC plus KFD is a promising mucosal vaccine candidate for protection against SARS-CoV-2 Omicron infection,pathology and transmission potential. | Jingyi Yang Mei-Qin Liu Lin Liu Xian Li Mengxin Xu Haofeng Lin Shuning Liu Yunqi Hu Bei Li Bowen Liu Min Li Ying Sun Yao-Qing Chen Zheng-Li Shi Huimin Yan | 2022 | Cellular & Molecular Immunology2022，19，11： | 3 |
| 2 | 不同解离液及解离条件下新型冠状病毒灭活疫苗中铝佐剂的解离效果显示文摘目的探讨不同解离液及解离条件下新型冠状病毒灭活疫苗中铝佐剂的解离效果。方法配制6种解离液(1~6),将新型冠状病毒灭活疫苗成品分别与6种解离液混合,于37℃解离20 h,ELISA法检测抗原含量,解离度最高的为最佳解离液。将新型冠状病毒灭活疫苗成品与最佳解离液混合,于室温或37℃分别解离2、10和20 h,ELISA法检测A450,以A450最高的解离条件为最佳。对最佳解离液及解离条件进行干扰试验及准确性、精密性、耐用性、适用性验证。结果最佳解离液为解离液5[0.1%(v/v)TritonX-100,0.1 mol/L EDTA,0.05%(v/v)Tween20],最佳解离条件为:37℃解离20 h。添加与未加解离液5的新型冠状病毒灭活疫苗原液检测结果差异无统计学意义(t=0.963,P>0.05);重复检测6次新型冠状病毒灭活疫苗参考品的抗原含量回收率在98.13%~100.63%之间;同一实验员于不同时间及不同实验员于同一时间重复检测6次结果的CV均<10%;解离16、20、24 h检测结果的CV均<10%,ELISA检测过程中终止反应后放置0、10、20 min检测结果的CV均<1%;4批新型冠状病毒灭活疫苗成品检测结果的CV均<10%。结论本研究确定的最佳解离液和解离条件效果较好,解离液干扰小,且准确性、精密性、耐用性和适用性良好,为新型冠状病毒灭活疫苗的质量控制提供了可靠的检测方法。 | 施金荣 申瑷琳 邓涛 潘俊杰 刘青 程小玲 罗敏 段凯 | 2022 | 中国生物制品学杂志2022，35，11： | 0 |
| 3 | Inactivated SARS-CoV-2 induces acute respiratory distress syndrome in human A CE2-transgenic mice显示文摘The development of animal models for COVID-19 is essential for basic research and drug/vaccine screening.Previously reported COVID-19 animal models need to be established under a high biosafety level condition for the utilization of live SARS-CoV-2,which greatly limits its application in routine research.Here,we gen erate a mouse model of COVID-19 un der a gen eral laboratory condition that captures multiple characteristics of SARS-CoV-2-induced acute respiratory distress syndrome(ARDS)observed in huma ns.Briefly,human ACE2-tra nsge nic(MCE2)mice were in tratracheally in stilled with the formaldehyde-inactivated SARS-CoV-2,resulting in a rapid weight loss and detrimental changes in lung structure and function.The pulmonary pathologic changes were characterized by diffuse alveolar damage with pulmonary consolidation,hemorrhage,necrotic debris,and hyaline membrane formation.The production of fatal cytokines(IL-β,TNF-α,and IL-6)and the infiltration of activated neutrophils,inflammatory monocyte-macrophages,and T cells in the lung were also determined,suggesting the activation of an adaptive immune response.Therapeutic strategies,such as dexamethasone or passive antibody therapy,could effectively ameliorate the disease progression in this model.Therefore,the established mouse model for SARS-CoV-2-induced ARDS in the current study may provide a robust tool for researchers in the standard open laboratory to investigate the pathological mechanisms or develop new therapeutic strategies for COVID-19 and ARDS. | Zhenfei Bi Weiqi Hong Haiying Que Cai He Wenyan Ren Jingyun Yang Tianqi Lu Li Chen Shuaiyao Lu Xiaozhong Peng Xiawei Wei | 2022 | Signal Transduction and Targeted Therapy2022，7，1： | 0 |
| 4 | 新型冠状病毒疫苗在非人灵长类动物模型中的效果评价进展显示文摘新型冠状病毒肺炎(corona virus disease 2019,COVID-19)是一种由严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)引起的广泛流行的急性呼吸道传染病,已经导致全球公共卫生危机,广泛接种疫苗是遏制COVID-19疫情最有效的手段之一。非人灵长类动物(non-human primates,NHP)在遗传学上与人亲缘关系相近,具有与人相似的解剖学、生理学与病理学特征,在合适的NHP模型中评价疫苗效果是疫苗研发中的重要步骤。现针对近期SARS-CoV-2候选疫苗在NHP模型中的效果评价进展作一概述,期望为SARS-CoV-2疫苗的开发提供参考。 | 陈云丰(综述) 卢佳 李新国(审校) | 2021 | 微生物学免疫学进展2021，49，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员